
Opinion|Videos|September 19, 2024
Exploring Outcomes From TROPION-Lung01 Presented at WCLC 2024
Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on overall survival outcomes in patients with lung cancer, with a particular focus on survival rates across different histological subtypes.
Advertisement
Advertisement
Related to this article

The designation supports development of elticertinib for patients with EGFR exon 20 insertion–mutated NSCLC progressing after platinum-based chemotherapy and amivantamab.

Updated THIO-101 data showed an 88% DCR with ateganosine followed by cemiplimab in third-line NSCLC after immunotherapy and chemotherapy.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
How Is AI Changing Breast Cancer Education?
3
Taking Weekends Off Dasatinib Maintains Responses in First-Line CML
4
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
5

